Gaining Ground on Breast Cancer: Global Power

Join Our Community of Science Lovers!

This story is a supplement to our feature "New Breast Cancer Treatments Help Sufferers Gain Ground" which was printed in the June 2008 issue of Scientific American.

Targeted therapies will be most powerful, in principle, when they are used together in combinations tailored to the tumor features driving an individual patient’s cancer. Clinical trials to test specific drug combinations provide critical information about which treatments work most effectively on different tumor profiles and reveal unexpected interactions between drugs. But trials take time, often years, to enroll a sufficient number of participants to generate statistically significant results. That is why multinational research consortia based in Europe and the U.S. are pooling resources to conduct a 50-country trial, the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study (ALTTO), which has just begun recruiting in the U.S.

Some 1,500 testing sites will treat patients with early (stage I or II) breast cancers that overproduce the HER2 protein, giving them chemotherapy and either trastuzumab or lapatinib alone, or one of those drugs followed by the other, or both drugs together. The trial will provide the first side-by-side comparison of these HER2-targeted treatments that work by different mechanisms.

On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

With a goal of including as many as 8,000 women on six continents, ALTTO has the potential to quickly generate results that can then be applied to patients everywhere. Moreover, this global data-sharing model can highlight differences in treatment responses or toxicity among different ethnic groups, a phenomenon observed with certain types of chemotherapy because of genetic variations that affect the way the drugs are metabolized by patients’ bodies. Having such information about the newer targeted therapies will help doctors to further personalize treatment, tailoring it to both the tumor and the patient.

—The Editors

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American